Haematopoietic growth factor (G-CSF)
Granulocyte colony-stimulating factor (G-CSF) indicated to decrease the incidence of infection, manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy, and to reduce the time to neutrophil recovery following induction/consolidation chemotherapy of acute myeloid leukemia.
Also known as: G-CSF, Neupogen, Nivestim
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
No documented drug–drug interactions for this medicine.
Filgrastim is given subcutaneously or intravenously; food does not affect its pharmacokinetics.
May be administered regardless of meals.
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
No relevant pharmacokinetic interaction; usual moderation during treatment.
Moderate alcohol intake.
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
Filgrastim can cause glomerulonephritis; patients with pre-existing renal disease are at increased risk of renal events.
Monitor renal function and proteinuria during treatment.
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
Filgrastim is associated with interstitial pneumonitis and adult respiratory distress syndrome, especially with concomitant chemotherapy.
Watch for respiratory symptoms and stop at signs of pneumonitis.
DailyMed approved label (NEUPOGEN, Amgen; setID 97cc73cc-b5b7-458a-a933-77b00523e193).
Data on filgrastim in pregnancy are limited; use only if the benefit outweighs the risk.
Avoid in pregnancy except in clearly indicated situations (e.g. severe neutropenia).
Excretion into breast milk is unknown; avoid during breastfeeding.
In women of childbearing age, rule out pregnancy before starting.
EMC-UK (MHRA) — approved Filgrastim SmPC: https://www.medicines.org.uk/emc/product/3000/smpc
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
G-CSF that regulates neutrophil production in the bone marrow, affecting proliferation, differentiation and selected end-cell functions of neutrophil progenitors (including enhanced phagocytosis and respiratory-burst priming). The effect is specific to the neutrophil lineage.
Binding to specific G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation commitment and functional activation of neutrophils.
Bioavailability of 60–70% after subcutaneous administration; serum peaks 2–8 h after dosing.
Predominantly renal clearance (eliminated mainly by the renal route).
Elimination half-life ~3.5 h (approximately 3.5 h after subcutaneous administration).
